Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ)

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) — VMCI valuation read

Headline read on 300573.SZ: VMCI of 57/100 versus a Healthcare sector median of 50. The 7-point above-median position is what makes Shenyang Xingqi Pharmaceutical Co.,Ltd a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 300573.SZ: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 300573.SZ: value (300573.SZ trades at 19.0x earnings, 6% above the Healthcare median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -1.5x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

300573.SZ rose 2.4% over the trailing 7 days, with a +1.6% read on a 30-day basis.